Compare American Homes 4 Rent Class A (AMH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Regeneron Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $34.07 (market cap $12.28B), while Regeneron Pharmaceuticals Inc trades at $796.95 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 6.7× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.87%). Which is the better fit depends on your goals.
| AMH | REGN | |
|---|---|---|
Market Cap | $12.28B | $82.06B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $812.27 |
52-Week Low | $27.38 | $555.51 |
Enterprise Value | $17.35B | $76.77B |
Dividend Yield | 3.87% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.87, down 0.76% today, with a bullish technical signal and strong fundamentals. The stock exhibits consistent earnings beats, with Q2 2026 FFO of $0.49 per share exceeding estimates (Zacks Investment Research, July 30, 2026). Revenue growth trends upward, reaching $1.85 billion in 2025, while net income margin improved to 25.53% in 2026. Recent news highlights institutional interest and raised 2026 guidance, supporting positive sentiment.
The outlook for AMH remains favorable due to robust operational performance and analyst consensus, but risks include regulatory changes affecting institutional home buying and high debt levels. With a $36.45 average price target and no sell ratings, Wall Street leans bullish, though investors should monitor housing policy impacts and interest rate sensitivity.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
